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Abstract
Intracardiac thrombus is often seen as a complication of ischemic heart disease (IHD) and non-ischemia
cardiomyopathies (NICM). The advancements in imaging modalities and therapeutic options have helped
reduce the complications arising from ventricular thrombi, such as systemic embolization. Here we present
two cases of intracardiac thrombus associated with coronavirus disease (COVID) 19, one with an apical
thrombus in the left ventricle and the other with a thrombus in the right ventricle adjacent to chordae
tendinae. The effects of covid-19 on the cardiovascular system are yet to be thoroughly evaluated. Venous
and arterial thrombosis is commonly associated with COVID-19 but in situ detection of intracardiac
thrombus has not been very frequently reported. Intracardiac thrombus and embolization pose a very high
risk of complications in COVID-19.
The coronavirus pandemic caused by SARS-CoV-2 during 2019-2021 has caused several deaths and has
resulted in many long-term consequences, many of which remain unclear. In-hospital complications from
COVID-19 are better reported due to constant monitoring. The ongoing, late, and chronic complications
arising from COVID-19 require more vigilant case-by-case screening and surveillance.

Categories: Emergency Medicine, Family/General Practice, Internal Medicine
Keywords: right ventricular thrombus, cardiomyopathy, covid-19 and cardiomyopathy, ventricular thrombus, corona
virus disease, covid-19

Introduction
The incidence of left ventricular thrombus is 15% in patients with ST elevated myocardial infarction (STEMI)
and 2-36% in patients with non-ischemic cardiomyopathies. The risk of systemic embolization increases
mortality and morbidity regardless of the etiology of the thrombus [1]. The advent of thrombolytic agents
has reduced the incidence of thrombus post-acute phase of myocardial infarction. The spectrum of
cardiovascular diseases in the COVID-19 range from myocardial injury to various cardiomyopathies and
thromboembolic events. The mechanisms resulting in these events include cytokine storm, virus-mediated
damage to organs, prothrombotic states, hypoxia, and the long duration of illness and its complications.
Though many complications of COVID-19 such as arterial and venous thromboembolism, cardiomyopathy
are reported across multiple articles, only a few cases of intracardiac thrombus due to COVID-19 have been
reported per se.

Case Presentation
Case 1
A 43-year-old female patient with a history of hypertension and diabetes mellitus presented to the
emergency department with complaints of dizziness, headache, increasing shortness of breath, dry cough,
weight gain, and leg swelling. The patient had a history of COVID-19 six months prior to this presentation,
which was diagnosed by the polymerase chain reaction (PCR). On examination, she was dyspneic, nonhypoxic, with a respiratory rate of 30/minute, blood pressure 176/110 mmHg, heart rate of 95 beats/minute.
She had bilateral pitting pedal edema. Cardiac examination revealed S1 S2 with S3 heard on auscultation.
Chest examination revealed crackles in the bilateral lung bases. She was started on supplemental oxygen
and intravenous diuretics. Chest X-ray showed interstitial infiltrates. Electrocardiogram showed normal
sinus rhythm with right bundle branch block (Figure 1).
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FIGURE 1: ECG showing normal sinus rhythm with right bundle branch
block

Echocardiography showed a globally reduced left ventricular ejection fraction of 25% and a left ventricular
apical mural thrombus of 1.8cm (Figure 2). A computed tomography scan of the brain showed evidence of
acute right temporal and occipital infarcts, left posterior parietal or watershed infarct in the left temporal
insula, findings suggestive of embolic thromboembolism. The patient was diagnosed with non-ischemic
cardiomyopathy secondary to COVID-19 with subsequent LV thrombus and emboli to the brain. The patient
was treated with antiplatelets, heparin, and antihypertensive medicines. The patient improved
symptomatically during the hospital course on the medical floor and was discharged home on
antihypertensive medications, diuretics, beta-blockers, and direct oral anticoagulants (DOACs).

2022 Karikalan et al. Cureus 14(3): e22883. DOI 10.7759/cureus.22883

2 of 7

FIGURE 2: Echocardiogram showing globally enlarged ventricles with
an apical thrombus in the left ventricle (blue arrowhead)

A repeat echocardiogram on outpatient follow-up after a month showed an improved LV ejection fraction of
45% and a 1.5cm mass at the LV apex. Her congestive heart failure continued to show improvement since her
discharge. Hence, beta-blockers and diuretics were continued with oral anticoagulation for left ventricular
thrombus.

Case 2
A 33-year-old male presented with complaints of shortness of breath on exertion and palpitations. The
patient had a history of COVID-19 pneumonia two months prior to this presentation via PCR testing. On
examination, the patient was afebrile, heart rate of 84 beats/min, regular, and blood pressure of 140/90
mmHg. On auscultation, S1 and S2 were regular in rhythm, and no S3 was heard. Abdomen, respiratory and
neurological examination was normal. EKG showed normal sinus rhythm (Figure 3).
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FIGURE 3: ECG showing normal sinus rhythm, no ST-T changes

An echocardiogram showed an ejection fraction of 60% with mitral and tricuspid regurgitation, enlarged
right ventricle, and a 1.3-cm mobile mass attached to the tricuspid valve chordae tendinae (Figure 4).

FIGURE 4: Echocardiogram showing clot in the right ventricle (yellow
arrowhead)

The right atrial pressure was 5 mmHg, and the right ventricular systolic pressure was 35 mmHg. There was
mild tricuspid regurgitation. The patient was started on diuretics with improvement in her dyspnea. He was
also started on direct oral anticoagulants. The patient showed improvement in symptoms and was
discharged home on oral apixaban on day 4 of hospitalization. The follow-up echocardiogram in three
months showed resolution of the thrombus, right atrial pressure was 5 mmHg, and right ventricular pressure
was 20 mmHg (Figure 5).
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FIGURE 5: Echocardiogram showing no thrombus in the RV

Discussion
Left ventricular thrombus (LVT) without myocardial infarction
Intracardiac thrombus is commonly seen after acute MI or non-ischemic cardiomyopathy with severely
reduced LV ejection fraction. With the advent of primary coronary intervention, the incidence has declined
from 40% to 5-15% [1, 2]. The other causes of ventricular thrombus include myocarditis, cardiomyopathy,
hypercoagulable states such as protein S and protein C deficiency, antiphospholipid syndrome, Behcet's
disease, and blunt chest trauma. The incidence of left ventricular thrombus in patients with non-ischemic
cardiomyopathy was found to be 2 to 36% [1]. Younger age, reduced ejection fraction, increased regional wall
motion, lesser deceleration time, increased early diastolic filling velocity, and high left atrium area
contributes to LVT in dilated cardiomyopathy. In stress-induced cardiomyopathy, the incidence of LVT was
found to be 3-5.3%, the reason for the lower incidence being the transient nature of the disease. The apex is
the most commonly involved region in the left ventricular thrombus in both MI and non-ischemic
cardiomyopathy patients [3]. Biventricular systolic dysfunction in dilated cardiomyopathy results in
biventricular stasis and can lead to thrombus formation in both the right and left ventricles, left being more
common than right [3]. In non-ischemic cardiomyopathy patients with LV thrombus, the frequency of
thrombus in other cardiac chambers is 40% higher than patients with Ischemic cardiomyopathy [4]. LV
thrombus is associated with an increased risk of peripheral embolization. The trouble arises when the
thrombus protrudes into the ventricular cavity or when the thrombus is highly mobile [5]. Such as the case
in our patient with left ventricular thrombus, where it embolized to the brain, causing an embolic stroke.
The mortality rate is higher in patients with peripheral embolization than patients with severe ventricular
dysfunction without embolization [5]. In all patients with reduced ejection fraction, screening for LVT should
be prioritized considering the embolic event and mortality risk.
Right ventricular thrombus is less frequent than LVT. The most common cause is deep vein thrombus. The
right ventricular thrombus is often said to be ‘in transit since they originate from the deep venous system
and travel from the periphery. Other causes include heart failure, intracardiac devices, and atrial fibrillation
[6]. RV thrombus can be of three types: Type A - serpiginous highly mobile mass within right atrium or
ventricle, Type B - non-mobile, mural, and Type C - similar to myxoma and highly portable. Type A is more
common and is most often associated with acute pulmonary embolism [7]. Fortunately, our patient
presented early and was diagnosed and treated, preventing the embolization of the right ventricular
thrombus and causing pulmonary embolism.
Trans-thoracic echocardiography (TTE) is the recommended screening tool for thrombus detection. The TTE
can be technically challenging due to patients’ body size, chest deformities, lung diseases, and small
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intercostal spaces. Though transoesophageal echocardiography (TEE) is considered superior to transthoracic
echocardiography, its role in LVT is limited. The use of echocardiographic contrast agent (ECA) and
harmonic imaging can improve the sensitivity and specificity of echocardiography. Cardiac magnetic
resonance (CMR) imaging is superior to all other imaging modalities. It facilitates the detection of
intraventricular structural abnormalities, scarred myocardium, etc.; yet, the higher cost and lesser
availability pose a hurdle for CMR usage even in developed countries. Computerized tomography (CT) for
LVT has the same accuracy as TTE, the only cons being increased radiation exposure and iodine contrast
agent usage.
According to the guidelines, the treatment of choice for left ventricular thrombus is warfarin for a minimum
of three to six months [8]. The use of warfarin requires monitoring of the international normalized ratio,
food and drug restrictions due to interactions, and the use of bridging therapy to overcome the
prothrombotic effect of vitamin K antagonist and the increased risk of bleeding [2]. The newer direct oral
anticoagulants are being used across a wide scale due to the advantages such as less monitoring, fewer
interactions, and the absence of a requirement of bridge therapy. The American Heart Association
guidelines recommend the usage of low molecular weight heparin (LMWH), dabigatran, rivaroxaban, or
apixaban for patients who are intolerant to warfarin therapy. Surgical thrombectomy is considered in
hemodynamically unstable patients or patients undergoing open-heart procedures where thrombus poses a
high risk for embolism. The mortality and morbidity associated with surgical thrombectomy outweigh the
benefits of performing surgery for the sole purpose of ventricular thrombus [1].
The right ventricular thrombus is often associated with pulmonary embolism. It is known to originate from
deep vein thrombus or in-situ due to cardiomyopathy or atrial fibrillation due to stagnation of blood [9].
There are no definitive guidelines for the management of right heart thrombus. Decisions are taken based on
case-by-case scenarios and are often followed as per pulmonary embolism protocols. Initial management
includes oxygen therapy, administration of right ventricular failure if present, followed by anticoagulation
[10]. In hemodynamically stable patients, anticoagulation is initiated with unfractionated heparin, or low
molecular weight heparin, followed later by oral anticoagulation. In case of hemodynamic severity or
instability thrombolysis, surgical embolectomy is chosen on a case-by-case basis. In patients with
recurrence and patients not suitable for medical and surgical treatment, the inferior vena cava (IVC) filter
can be considered. As our patient was hemodynamically stable, he was started on LMWH and discharged
with oral anticoagulants [10].

COVID-19 and hemostatic complications
The outbreak of COVID-19, caused by the SARS-CoV-2 virus, has affected more than 300 million people
worldwide and caused approximately 5.5 million deaths. Despite being a primary lung disease, the cytokine
storm causes an imbalance between T-cells and interleukin-6 (IL-6), IL-17, and other cytokines resulting in
multiple organ damage [11]. The hemostatic complications such as ischemic stroke, deep vein thrombosis,
acute pulmonary embolism seem to be higher in COVID-19 patients than non-COVID-19 patients [12].
Angiotensin-converting enzyme receptors are present in multiple organs. The SARS-CoV-2 virus binds to the
ACE receptors, triggering endothelial dysfunction, which sets in recruitments of inflammatory mediators
resulting in activation of the complement system. Prolonged bed rest due to hospital admission causes blood
stasis. This results in thrombocytopenia, long prothrombin time (PT), international normalized ratio (INR),
and thrombin time (TT). Another pathophysiology is neutrophils extracellular traps (NET) released by
neutrophils [11]. COVID-19 can begin with cardiovascular diseases or can cause exacerbation of pre-existing
cardiovascular illness. The post covid cardiovascular sequelae include presentations such as coronary
syndrome, heart failure, cardiomyopathy, myocardial infarction, arrhythmias, and venous
thromboembolism.
The patients presented above have no evidence of infarction. Myocardial injury due to SARS-CoV-2 infection
could have resulted in cardiomyopathy, resulting in stagnation of blood, which might have resulted in
ventricular thrombus formation. Younger age, non-ischemic cardiomyopathy supported using direct oral
anticoagulants for their management. The patient’s follow-up with left ventricular thrombus post-initiation
of DOAC showed echocardiographic evidence of reduction of thrombus size from 1.8 cm to 1.5 cm. Risk
stratification for venous thromboembolism should be carried out in patients with COVID-19, similar to nonCOVID-19 patients, considering the risks of acute illness and prolonged immobilization. Post-discharge
prophylaxis with low molecular weight heparin or DOACs can be provided based on risk assessment at the
time of discharge.

Conclusions
COVID-19, despite being a primary respiratory disease, is known to cause new-onset cardiovascular illness
and complicate existing cardiovascular conditions. The severity of acute illness, the requirement of
prolonged hospitalization, the inflammatory nature of SARS-CoV-2 predisposes to thromboembolic
complications, both during the illness and post-discharge. Intracardiac thrombosis in COVID-19 patients is
not a frequently reported entity and can have significant associated mortality and morbidity. Thus, longterm follow-up of these patients and data sharing across multiple countries can aid in a proper
understanding of the pathophysiology, management, and prevention of this condition.
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